News & Events zu ICU Medical Inc (ICUI)ICUIICU Medical Inc

ICU Medical Q2 Revenue Exceeds Expectations at $551.68M

Reports Q2 revenue $551.68M, consensus $534.21M. Vivek Jain, ICU Medical's Chief Executive Officer, said, "Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business."

Company Raises FY26 Adjusted EBITDA Outlook to $415M-$435M

Consensus $8.16. Raises FY26 adjusted EBITDA view to $415M-$435M from $400M-$430M. The company said, "For Fiscal Year 2026 the Company is updating its estimates of GAAP net income from a range of $26 million to $44 million to a range of $73 million to $83 million and GAAP diluted earnings per share from a range of $1.03 to $1.74 to a range of $2.89 to $3.29. The Company is updating the estimate of its full year 2026 guidance of Adjusted EBITDA from a range of $400 million to $430 million to a range of $415 million to $435 million and diluted earnings per share from a range of $7.75 to $8.45 to a range of $8.60 to $9.00."

ICU Medical Reports Q1 Revenue of $530.23M

Reports Q1 revenue $530.23M, consensus $531.12M. Vivek Jain, ICU Medical's Chief Executive Officer, said, "First quarter results were generally in line with our expectations."